Chronic Myeloid Leukemia News
This population-based study of patients with chronic phase CML evaluated the BCR/ABL1 TKI discontinuation rates for patients treated on and off a clinical trial.
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Lack of initial response to imatinib might indicate need to switch to dasatinib.
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
Research into opioid alternatives for cancer-related pain has stalled, however substance use disorders remain problematic.
Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
Out-of-pocket spending remains high for many patients with blood cancers who are receiving tyrosine kinase inhibitors and immunomodulatory drugs.
The cancer field is not immune to the challenges of out-of-network and surprise billing.
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
Asciminib appeared to have clinical activity in a population of heavily pretreated patients with chronic myeloid leukemia, including those with a T315I mutation.
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators.
ASCO officials examined the discrepancies in financial disclosures across platforms and call for a simplified system.